Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 6/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | MPL | P40238 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341519 | 0.90 | MLYCD (0.56) | MLYCDMAPK14MPLBRD4SRC | |
| SCHEMBL1882287 | 0.84 | MAPK14 (0.56) | MLYCDMAPK14MPLBRD4KDR | |
| SCHEMBL4335463 | 0.82 | MAPK14 (0.57) | MLYCDMAPK14BRD4SRCBRAF | |
| SCHEMBL4332772 | 0.81 | MAPK14 (0.62) | MLYCDMAPK14BRD4NPC1RAB9A | |
| SCHEMBL27765849 | 0.80 | MAPK14 (0.54) | MLYCDMAPK14NPC1RAB9AMAPK9 | |
| SCHEMBL4327769 | 0.80 | BRD4 (0.60) | MLYCDMAPK14BRD4KIF11NPC1 | |
| SCHEMBL4339786 | 0.79 | MAPK14 (0.63) | MLYCDMAPK14MPLMAPK9MAPK10 | |
| SCHEMBL4335175 | 0.78 | MAPK14 (0.61) | MLYCDMAPK14BRD4NPC1RAB9A | |
| SCHEMBL4341435 | 0.77 | MAPK14 (0.68) | MLYCDMAPK14SRCBRAFKDR | |
| SCHEMBL4339480 | 0.77 | MAPK14 (0.57) | MLYCDMAPK14SRCBRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MLYCD 4475/4885MAPK14 43/4885MPL 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.